Core Viewpoint - Yinos (688710.SH) announced that the Aopeng Partnership Plan will reduce its shareholding in the company by up to 1.4 million shares, representing no more than 1% of the total share capital, within three months after the announcement [1] Group 1 - The Aopeng Partnership is an employee stock ownership platform for the company [1] - Some of the company's directors, senior management, and core technical personnel hold shares indirectly through this employee stock ownership platform [1] - The reduction of shares will be conducted through centralized bidding and will not exceed 1% of the total shares within any consecutive 90-day period [1]

翱鹏合伙为公司员工持股平台，公司部分董事、高级管理人员及核心技术人员通过该员工持股平台间接 持有公司股份。 益诺思(688710.SH)发布公告，翱鹏合伙计划自公告披露之日起15个交易日后的3个月内，通过集中竞价 交易方式减持其所持有的公司股份数量不超过140.98万股，占公司总股本的比例不超过1%，且在任意 连续90个自然日内，减持的股份总数不超过公司股份总数的1%。 ...

股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 证券代码：688710 证券简称：益诺思 公告编号：2025-045 上海益诺思生物技术股份有限公司 重要内容提示： 股东持股的基本情况 截至本公告披露日，上海翱鹏企业管理中心（有限合伙）（以下简称"翱 鹏合伙"）持有上海益诺思生物技术股份有限公司（以下简称"公司"）17,412,396 股，占公司总股本的 12.35%。翱鹏合伙为公司员工持股平台，公司部分董事、 高级管理人员及核心技术人员通过该员工持股平台间接持有公司股份。 减持计划的主要内容 翱鹏合伙计划自本公告披露之日起 15 个交易日后的 3 个月内，通过集中竞 价交易方式减持其所持有的公司股份数量不超过 1,409,796 股，占公司总股本的 比例不超过 1.00%，且在任意连续 90 个自然日内，减持的股份总数不超过公司 股份总数的 1.00%。减持价格按市场价格确定，若在上述减持计划实施期间，公 司发生派发红利、送红股、转增股本、增发新股或配股等股本变动、除权除息事 项，则上述 ...

益诺思公告，持股1741.24万股、占12.35%的股东上海翱鹏企业管理中心（有限合伙）计划自公告披露 之日起15个交易日后的3个月内，即2026年1月14日～2026年4月13日，通过集中竞价方式减持不超过 140.98万股，占公司总股本的1.00%，并在任意连续90个自然日内减持比例不超过1.00%；减持价格按届 时市场价格确定。 ...

Core Viewpoint - The pharmaceutical sector is showing resilience in the current market, with significant activity in both A-shares and Hong Kong stocks, particularly in the medical and innovative drug segments, indicating a potential opportunity for investment in medical assets [1][3][4]. Group 1: A-share Market Insights - The medical sector in the A-share market continues to rebound strongly, with the largest medical ETF (512170) rising over 1% and surpassing the annual line [1]. - Private hospitals and AI medical-related stocks are leading the gains, with Meinian Health achieving two consecutive trading limits and Weining Health rising over 7% [1]. - The pharmaceutical sector shows mixed performance, with traditional Chinese medicine leader Pian Zai Huang increasing over 1%, while innovative drug stocks such as Gan Li Pharmaceutical and Hai Si Ke fell by 1% [1]. - The medical ETF (512170) has seen a significant inflow of over 93 million yuan in the last 10 days, indicating strong buying interest [1]. Group 2: Hong Kong Market Insights - The Hong Kong pharmaceutical market is performing well, with the Hang Seng Index and Hang Seng Tech Index both in the red, while leading innovative drug stocks like BeiGene and CSPC Pharmaceutical are up by over 1% and 3%, respectively [3]. - The Hong Kong Innovation Drug ETF (520880) has experienced continuous net subscriptions for eight days, with its fund size reaching a record high of 4.176 billion shares [3]. - The medical theme sector in Hong Kong is also seeing significant gains, particularly in AI medical and medical device stocks, with MicroPort Medical rising by 8% [3]. Group 3: Industry Trends and Opportunities - Recent developments in the innovative drug sector include significant overseas collaborations, such as Heng Rui Pharmaceutical's partnership with Kailera for clinical research and a $90 million upfront payment deal between Heptares Therapeutics and BMS [4][5]. - The CXO (Contract Research Organization) sector is showing clear upward momentum, with increasing orders and performance indicators suggesting a positive trend [4]. - The innovative medical device sector is gaining attention from major global companies, indicating a potential for growth and value realization similar to the previous year's innovative drug sector [5]. Group 4: Investment Strategies - Various ETFs are available for investment in the pharmaceutical sector, including the Hong Kong Innovation Drug ETF (520880) and the A-share medical ETF (512170), which are positioned to capture growth in innovative drugs and medical services [6]. - The Hong Kong medical ETF (159137) is currently being launched, providing additional investment options in the medical theme sector [3][6].

Company Overview - Yinos Bio is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010. The company specializes in providing non-clinical research services in the biopharmaceutical sector, primarily as a Contract Research Organization (CRO) [1] - The company's revenue composition is as follows: non-clinical services account for 96.31%, clinical services for 3.42%, and other services for 0.27% [1] Stock Performance - As of December 18, Yinos Bio's stock price increased by 2.03%, reaching 51.36 CNY per share, with a total market capitalization of 7.241 billion CNY [1] - Year-to-date, the stock price has risen by 45.95%, with a 19.16% increase over the last five trading days, a 10.64% increase over the last 20 days, and a 9.63% increase over the last 60 days [1] Financial Performance - For the period from January to September 2025, Yinos Bio reported a revenue of 571 million CNY, representing a year-on-year decrease of 35.33%. The net profit attributable to shareholders was -14.7881 million CNY, a decline of 111.14% compared to the previous year [2] Shareholder Information - As of September 30, the number of shareholders for Yinos Bio was 4,849, a decrease of 9.97% from the previous period. The average number of circulating shares per person increased by 257.28% to 18,703 shares [2] - The company has distributed a total of 45.1135 million CNY in dividends since its A-share listing [3] - Notable changes in institutional holdings include new entries from Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund among the top ten circulating shareholders [3]

Group 1 - The core viewpoint of the article highlights the significant rise in the stock price of Zhaoyan New Drug (6127.HK), which increased nearly 10% to HKD 22.48, marking a two-month high, with a cumulative increase of over 30% in December, leading to a total market capitalization of HKD 16.86 billion [1] - The price of experimental monkeys has surged, with the cost of 3-5 year old crab-eating macaques reaching HKD 140,000 each, indicating a supply-demand imbalance this year [1] - The recovery in the CRO (Contract Research Organization) industry and the upward cycle of innovative drugs are contributing factors to the rising prices of experimental monkeys, with several CRO companies, including Zhaoyan New Drug and Yinos, having substantial resources in this area [1] Group 2 - According to Founder Securities, leading CROs with rich strategic resource reserves are expected to benefit from the industry recovery and the fair value gains from monkey prices [1] - For Zhaoyan New Drug, assuming an average price of HKD 84,900 per monkey in 2024 and an increase to HKD 140,000 by Q4 2025, with an estimated output rate of 17% from 23,200 monkeys, the projected new fair value in 2025 could be approximately HKD 220 million [1]

Group 1 - The core viewpoint of the article highlights the significant rise in the stock price of Zhaoyan New Drug (6127.HK), which increased nearly 10% to HKD 22.48, marking a two-month high, with a cumulative increase of over 30% in the month, resulting in a total market capitalization of HKD 16.86 billion [1] - The price of experimental monkeys has surged, with the cost for 3-5 year old crab-eating macaques reaching HKD 140,000 each, indicating a supply-demand imbalance this year [1] - The increase in monkey prices is linked to the upward cycle of innovative drugs and the recovery of orders in the CRO industry, with several CRO companies, including Zhaoyan New Drug and Yinos, having substantial resources in experimental monkeys [1] Group 2 - According to Founder Securities, leading CROs with rich strategic resource reserves are expected to benefit from the industry recovery and the fair value gains from monkey prices [1] - For Zhaoyan New Drug, assuming an average price of HKD 84,900 per monkey in 2024 and an increase to HKD 140,000 by Q4 2025, with an estimated output rate of 17% from a known 23,200 monkeys, the projected new fair value in 2025 could be approximately HKD 220 million [1]

Core Insights - The article highlights the successful collaboration between the Haimen High-tech Zone and the Changjiang Drug Research Institute, which has accelerated the development and commercialization of pharmaceutical products, exemplified by the rapid development of fish bladder-derived active peptide products [1][2]. Group 1: Collaborative Innovation - The partnership between the Haimen High-tech Zone and the Changjiang Drug Research Institute has led to a significant reduction in the development timeline for pharmaceutical products, achieving results in just six months instead of the usual three to five years [1]. - The collaboration has resulted in the establishment of a dual demand and problem-solving list, facilitating targeted research and development efforts that have saved companies over 5 million yuan in costs [2]. Group 2: Talent Development - The Changjiang Drug Research Institute has partnered with nearly 20 universities and research institutions to create a joint graduate training base, fostering a seamless connection between classroom learning, laboratory work, and production [3]. - Over the past six years, this initiative has produced more than 300 professional master's graduates and 200 high-end industry workers, with 80% choosing to start their careers within the Haimen High-tech Zone [3]. Group 3: Future Prospects - Looking ahead, the Changjiang Drug Research Institute plans to focus on cutting-edge fields such as anti-tumor drugs and medical devices during the 14th Five-Year Plan period, while the Haimen High-tech Zone aims to enhance its pilot platform and optimize talent policies [3]. - The goal is to create a comprehensive innovation ecosystem that integrates basic research, technical problem-solving, result transformation, and industrial application, ultimately establishing Haimen as a national hub for industry-academia-research collaboration [3].

Core Viewpoint - Shanghai Yinos Biotechnology Co., Ltd. has been awarded the "2025 Most Socially Responsible Listed Company Award" for its outstanding practices in social responsibility and professional service capabilities, highlighting its deep accumulation and core value in the CRO professional segment [1][3] Company Overview - Yinos is a comprehensive R&D service (CRO) company specializing in non-clinical research services for biomedicine, adhering to the core values of "science-led, quality-first, integrity, and win-win cooperation" [3] - The company focuses on major national biomedicine development needs and plays a significant role in drug evaluation services, contributing to the high-quality development of the biomedicine industry [3] Business Performance - In Q3 2025, Yinos achieved operating revenue of 195 million yuan, a quarter-on-quarter increase of 17.71%, maintaining a steady growth trend [4] - The company saw a 29.37% year-on-year increase in new order amounts, with significant growth in new drug clinical trial applications (IND) and new drug marketing applications (NDA), which rose by 30.71% and 23.06% respectively [4] Market Position and Strategy - Yinos is positioned as a leading enterprise in the CRO industry, benefiting from a high-growth cycle and possessing technical advantages that meet high-end demand across the entire service chain [4] - The company has established a non-clinical drug metabolism platform compliant with ICH, FDA, and NMPA standards, enhancing its capabilities in radiolabeled isotopes and imaging evaluation research [4] Innovation and International Expansion - Yinos is continuously advancing frontier technologies, particularly in small nucleic acid drugs and CAR-T cell therapy, establishing a comprehensive technical service matrix [5][6] - The company has expanded its international market presence, with significant growth in new order amounts from overseas, enhancing its brand influence and recognition [6] Future Outlook - The award received is not only a recognition of past achievements but also an expectation for future development, as CRO companies play an increasingly important role in new drug development [6] - Yinos aims to leverage this award to strengthen its professional advantages while actively fulfilling social responsibilities, contributing to the high-quality development of China's biomedicine industry [6]